Daniel C Javitt

List of Publications by Year
in descending order

118 papers	11,871 citations	30070 54 h-index	28297 105 g-index
120 all docs	120 docs citations	120 times ranked	9812 citing authors

#	Article	IF	Citations
1	Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neurosciences, 2008, 31, 234-242.	8.6	896
2	Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers. Archives of General Psychiatry, 2000, 57, 1139.	12.3	552
3	Glutamate and Schizophrenia: Phencyclidine, Nâ€Methylâ€dâ€Aspartate Receptors, and Dopamineâ€“Glutamate Interactions. International Review of Neurobiology, 2007, 78, 69-108.	2.0	463
4	Automated analysis of free speech predicts psychosis onset in high-risk youths. NPJ Schizophrenia, 2015, 1, 15030.	3.6	453
5	When Doors of Perception Close: Bottom-up Models of Disrupted Cognition in Schizophrenia. Annual Review of Clinical Psychology, 2009, 5, 249-275.	12.3	441
6	The Spectrotemporal Filter Mechanism of Auditory Selective Attention. Neuron, 2013, 77, 750-761.	8.1	399
7	Somatosensory Input to Auditory Association Cortex in the Macaque Monkey. Journal of Neurophysiology, 2001, 85, 1322-1327.	1.8	368
8	N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?. Brain Research Bulletin, 2010, 83, 108-121.	3.0	340
9	Early-Stage Visual Processing and Cortical Amplification Deficits in Schizophrenia. Archives of General Psychiatry, 2005, 62, 495.	12.3	325
10	Auditory dysfunction in schizophrenia: integrating clinical and basic features. Nature Reviews Neuroscience, 2015, 16, 535-550.	10.2	312
11	Sensory Processing Dysfunction in the Personal Experience and Neuronal Machinery of Schizophrenia. American Journal of Psychiatry, 2015, 172, 17-31.	7.2	306
12	Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments. Brain, 2007, 130, 417-430.	7.6	291
13	Neurophysiological biomarkers for drug development in schizophrenia. Nature Reviews Drug Discovery, 2008, 7, 68-83.	46.4	283
14	Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia. Schizophrenia Bulletin, 2012, 38, 958-966.	4.3	268
15	Associated deficits in mismatch negativity generation and tone matching in schizophrenia. Clinical Neurophysiology, 2000, 111, 1733-1737.	1.5	255
16	Deficits in Auditory and Visual Context-Dependent Processing in Schizophrenia. Archives of General Psychiatry, 2000, 57, 1131.	12.3	210
17	Impaired mismatch negativity (MMN) generation in schizophrenia as a function of stimulus deviance, probability, and interstimulus/interdeviant interval. Electroencephalography and Clinical Neurophysiology - Evoked Potentials, 1998, 108, 143-153.	2.0	197
18	Sensory Contributions to Impaired Prosodic Processing in Schizophrenia. Biological Psychiatry, 2005, 58, 56-61.	1.3	189

#	Article	IF	Citations
19	Impaired precision, but normal retention, of auditory sensory ("echoic") memory information in schizophrenia.. Journal of Abnormal Psychology, 1997, 106, 315-324.	1.9	184
20	Magnocellular Pathway Impairment in Schizophrenia: Evidence from Functional Magnetic Resonance Imaging. Journal of Neuroscience, 2008, 28, 7492-7500.	3.6	183
21	A Roadmap for the Development and Validation of Event-Related Potential Biomarkers in Schizophrenia Research. Biological Psychiatry, 2011, 70, 28-34.	1.3	163
22	Auditory Sensory Dysfunction in Schizophrenia. Archives of General Psychiatry, 2000, 57, 1149.	12.3	156
23	Demonstration of mismatch negativity in the monkey. Electroencephalography and Clinical Neurophysiology, 1992, 83, 87-90.	0.3	155
24	Translating Glutamate: From Pathophysiology to Treatment. Science Translational Medicine, 2011, 3, 102mr2.	12.4	147
25	Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings. Schizophrenia Research, 2014, 152, 325-332.	2.0	144
26	Impairments in generation of early-stage transient visual evoked potentials to magno- and parvocellular-selective stimuli in schizophrenia. Clinical Neurophysiology, 2005, 116, 2204-2215.	1.5	132
27	Getting the Cue: Sensory Contributions to Auditory Emotion Recognition Impairments in Schizophrenia. Schizophrenia Bulletin, 2010, 36, 545-556.	4.3	129
28	D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry,the, 2015, 2, 403-412.	7.4	128
29	The Neural Substrates of Impaired Prosodic Detection in Schizophrenia and Its Sensorial Antecedents. American Journal of Psychiatry, 2007, 164, 474-482.	7.2	122
30	Early Sensory Contributions to Contextual Encoding Deficits in Schizophrenia. Archives of General Psychiatry, 2011, 68, 654.	12.3	122
31	Magnocellular and parvocellular contributions to backward masking dysfunction in schizophrenia. Schizophrenia Research, 2003, 64, 91-101.	2.0	121
32	â€œItâ€™s not what you say, but how you say itâ€• a reciprocal temporo-frontal network for affective prosody. Frontiers in Human Neuroscience, 2010, 4, 19.	2.0	108
33	Predictive Suppression of Cortical Excitability and Its Deficit in Schizophrenia. Journal of Neuroscience, 2013, 33, 11692-11702.	3.6	106
34	Reading impairment and visual processing deficits in schizophrenia. Schizophrenia Research, 2006, 87, 238-245.	2.0	101
35	Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists. Neuropsychopharmacology, 2004, 29, 300-307.	5.4	100
36	Auditory Emotion Recognition Impairments in Schizophrenia: Relationship to Acoustic Features and Cognition. American Journal of Psychiatry, 2012, 169, 424-432.	7.2	99

#	Article	IF	Citations
37	Twenty-five Years of Glutamate in Schizophrenia: Are We There Yet?. Schizophrenia Bulletin, 2012, 38, 911-913.	4.3	98
38	Reading Deficits in Schizophrenia and Individuals at High Clinical Risk: Relationship to Sensory Function, Course of Illness, and Psychosocial Outcome. American Journal of Psychiatry, 2014, 171, 949-959.	7.2	98
39	Thinking Glutamatergically: Changing Concepts of Schizophrenia Based Upon Changing Neurochemical Models. Clinical Schizophrenia and Related Psychoses, 2010, 4, 189-200.	1.4	98
40	Neurocognitive and symptom correlates of daily problem-solving skills in schizophrenia. Schizophrenia Research, 2006, 83, 237-245.	2.0	88
41	Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. Schizophrenia Research, 2018, 191, 70-79.	2.0	88
42	Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders. JAMA Psychiatry, 2018, 75, 11.	11.0	88
43	Consequences of Magnocellular Dysfunction on Processing Attended Information in Schizophrenia. Cerebral Cortex, 2012, 22, 1282-1293.	2.9	84
44	Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine. Brain, 2016, 139, 3281-3295.	7.6	84
45	Neural Substrates of Auditory Emotion Recognition Deficits in Schizophrenia. Journal of Neuroscience, 2015, 35, 14909-14921.	3.6	80
46	Mismatch negativity as a biomarker of theta band oscillatory dysfunction in schizophrenia. Schizophrenia Research, 2018, 191, 51-60.	2.0	79
47	Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Current Opinion in Psychiatry, 2006, 19, 151-157.	6.3	78
48	Differential Relationships of Mismatch Negativity and Visual P1 Deficits to Premorbid Characteristics and Functional Outcome in Schizophrenia. Biological Psychiatry, 2012, 71, 521-529.	1.3	76
49	Loneliness in schizophrenia and its possible correlates. An exploratory study. Psychiatry Research, 2016, 246, 211-217.	3.3	72
50	Theory of Mind (ToM) and counterfactuality deficits in schizophrenia: misperception or misinterpretation?. Psychological Medicine, 2006, 36, 1075-1083.	4.5	69
51	Neurophysiological models for new treatment development in schizophrenia: early sensory approaches. Annals of the New York Academy of Sciences, 2015, 1344, 92-104.	3.8	64
52	ReplacingDSMCategorical Analyses With Dimensional Analyses in Psychiatry Research. JAMA Psychiatry, 2015, 72, 1159.	11.0	64
53	Meta-analysis of mismatch negativity to simple versus complex deviants in schizophrenia. Schizophrenia Research, 2018, 191, 25-34.	2.0	64
54	Understanding tDCS effects in schizophrenia: a systematic review of clinical data and an integrated computation modeling analysis. Expert Review of Medical Devices, 2014, 11, 383-394.	2.8	61

#	Article	IF	Citations
55	Reduction in Tonal Discriminations Predicts Receptive Emotion Processing Deficits in Schizophrenia and Schizoaffective Disorder. Schizophrenia Bulletin, 2013, 39, 86-93.	4.3	59
56	The Thalamocortical Circuit of Auditory Mismatch Negativity. Biological Psychiatry, 2020, 87, 770-780.	1.3	58
57	The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. Journal of Psychiatric Research, 2019, 108, 57-83.	3.1	54
58	Continuous Phencyclidine Treatment Induces Schizophrenia-Like Hyperreactivity of Striatal Dopamine Release. Neuropsychopharmacology, 2001, 25, 157-164.	5.4	52
59	Differential Patterns of Visual Sensory Alteration Underlying Face Emotion Recognition Impairment and Motion Perception Deficits in Schizophrenia and Autism Spectrum Disorder. Biological Psychiatry, 2019, 86, 557-567.	1.3	51
60	A roadmap for development of neuro-oscillations as translational biomarkers for treatment development in neuropsychopharmacology. Neuropsychopharmacology, 2020, 45, 1411-1422.	5.4	51
61	Contributions of early cortical processing and reading ability to functional status in individuals at clinical high risk for psychosis. Schizophrenia Research, 2015, 164, 1-7.	2.0	46
62	Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder. Translational Psychiatry, 2021, 11, 419.	4.8	45
63	Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia. Neuropsychopharmacology, 2018, 43, 571-582.	5.4	44
64	Pupillometer-based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis.. Psychiatric Rehabilitation Journal, 2017, 40, 33-42.	1.1	43
65	Significant improvement in treatment resistant auditory verbal hallucinations after 5 days of double-blind, randomized, sham controlled, fronto-temporal, transcranial direct current stimulation (tDCS): A replication/extension study. Brain Stimulation, 2019, 12, 981-991.	1.6	39
66	Impaired magnocellular/dorsal stream activation predicts impaired reading ability in schizophrenia. NeuroImage: Clinical, 2013, 2, 8-16.	2.7	37
67	Neurofilament light interaction with GluN1 modulates neurotransmission and schizophrenia-associated behaviors. Translational Psychiatry, 2018, 8, 167.	4.8	37
68	Impaired Motion Processing in Schizophrenia and the Attenuated Psychosis Syndrome: Etiological and Clinical Implications. American Journal of Psychiatry, 2018, 175, 1243-1254.	7.2	35
69	Sensory and cross-network contributions to response inhibition in patients with schizophrenia. NeuroImage: Clinical, 2018, 18, 31-39.	2.7	34
70	Abnormal task modulation of oscillatory neural activity in schizophrenia. Frontiers in Psychology, 2013, 4, 540.	2.1	33
71	Neural oscillatory deficits in schizophrenia predict behavioral and neurocognitive impairments. Frontiers in Human Neuroscience, 2015, 9, 371.	2.0	32
72	A tale of two sites: Differential impairment of frequency and duration mismatch negativity across a primarily inpatient versus a primarily outpatient site in schizophrenia. Schizophrenia Research, 2018, 191, 10-17.	2.0	32

#	Article	IF	Citations
73	Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene. Biological Psychiatry, 2019, 86, 523-535.	1.3	32
74	Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers. Neuropsychopharmacology, 2020, 45, 1842-1850.	5.4	32
75	Inflammatory biomarkers in psychosis and clinical high risk populations. Schizophrenia Research, 2019, 206, 440-443.	2.0	30
76	Impact of baseline early auditory processing on response to cognitive remediation for schizophrenia. Schizophrenia Research, 2019, 208, 397-405.	2.0	30
77	Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients. Neuropsychopharmacology, 2020, 45, 1339-1345.	5.4	30
78	Mismatch negativity (MMN) to spatial deviants and behavioral spatial discrimination ability in the etiology of auditory verbal hallucinations and thought disorder in schizophrenia. Schizophrenia Research, 2018, 191, 140-147.	2.0	29
79	Differential profiles in auditory social cognition deficits between adults with autism and schizophrenia spectrum disorders: A preliminary analysis. Journal of Psychiatric Research, 2016, 79, 21-27.	3.1	28
80	Bimodal distribution of tone-matching deficits indicates discrete pathophysiological entities within the syndrome of schizophrenia. Translational Psychiatry, 2019, 9, 221.	4.8	28
81	Hierarchical deficits in auditory information processing in schizophrenia. Schizophrenia Research, 2019, 206, 135-141.	2.0	28
82	A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms. NeuroImage: Clinical, 2019, 22, 101739.	2.7	27
83	Fractal Dimension Analysis of Subcortical Gray Matter Structures in Schizophrenia. PLoS ONE, 2016, 11, e0155415.	2.5	27
84	Glycine modulators in schizophrenia. Current Opinion in Investigational Drugs, 2002, 3, 1067-72.	2.3	27
85	Mismatch negativity: A simple and useful biomarker of N-methyl-d-aspartate receptor (NMDAR)-type glutamate dysfunction in schizophrenia. Schizophrenia Research, 2018, 191, 1-4.	2.0	26
86	Targeting glutamate to treat schizophrenia: lessons from recent clinical studies. Psychopharmacology, 2016, 233, 2425-2428.	3.1	22
87	Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study. Psychiatry Research, 2019, 275, 78-85.	3.3	21
88	Developmental trajectory of mismatch negativity and visual event-related potentials in healthy controls: Implications for neurodevelopmental vs. neurodegenerative models of schizophrenia. Schizophrenia Research, 2018, 191, 101-108.	2.0	17
89	Deficits and compensation: Attentional control cortical networks in schizophrenia. NeuroImage: Clinical, 2020, 27, 102348.	2.7	17
90	The importance of a good night's sleep: An open-label trial of the sodium salt of Î³-hydroxybutyric acid in insomnia associated with schizophrenia. Schizophrenia Research, 2010, 120, 225-226.	2.0	16

#	Article	IF	Citations
91	Implicit emotion perception in schizophrenia. Journal of Psychiatric Research, 2015, 71, 112-119.	3.1	16
92	Auditory tasks for assessment of sensory function and affective prosody in schizophrenia. Comprehensive Psychiatry, 2014, 55, 1862-1874.	3.1	15
93	Current and Emergent Treatments for Symptoms and Neurocognitive Impairment in Schizophrenia. Current Treatment Options in Psychiatry, 2014, 1, 107-120.	1.9	15
94	Neural and functional correlates of impaired reading ability in schizophrenia. Scientific Reports, 2019, 9, 16022.	3.3	15
95	A century of sensory processing dysfunction in schizophrenia. European Psychiatry, 2019, 59, 77-79.	0.2	15
96	Failure to engage the temporoparietal junction/posterior superior temporal sulcus predicts impaired naturalistic social cognition in schizophrenia. Brain, 2021, 144, 1898-1910.	7.6	14
97	Immediate affective motivation is not impaired in schizophrenia. Schizophrenia Research, 2014, 159, 157-163.	2.0	13
98	The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to disease. Schizophrenia Research, 2022, 242, 56-61.	2.0	12
99	Biotypes in Psychosis: Has the RDoC Era Arrived?. American Journal of Psychiatry, 2016, 173, 313-314.	7.2	11
100	What you see is what you get: visual scanning failures of naturalistic social scenes in schizophrenia. Psychological Medicine, 2021, 51, 2923-2932.	4.5	11
101	Neurophysiological, Oculomotor, and Computational Modeling of Impaired Reading Ability in Schizophrenia. Schizophrenia Bulletin, 2021, 47, 97-107.	4.3	11
102	Complementary fMRI and EEG evidence for more efficient neural processing of rhythmic vs. unpredictably timed sounds. Frontiers in Psychology, 2015, 6, 1663.	2.1	10
103	Deficits in Pre-attentive Processing of Spatial Location and Negative Symptoms in Subjects at Clinical High Risk for Schizophrenia. Frontiers in Psychiatry, 2020, 11, 629144.	2.6	10
104	Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058. Neuropsychopharmacology, 2022, 47, 711-718.	5.4	10
105	Are basic auditory processes involved in source-monitoring deficits in patients with schizophrenia?. Schizophrenia Research, 2019, 210, 135-142.	2.0	8
106	Translational neurophysiological biomarkers of N-methyl-d-aspartate receptor dysfunction in serine racemase knockout mice. Biomarkers in Neuropsychiatry, 2020, 2, 100019.	1.0	8
107	Reply: A few remarks on assessing magnocellular sensitivity in patients with schizophrenia. Brain, 2007, 130, e84-e84.	7.6	7
108	Computational modeling of excitatory/inhibitory balance impairments in schizophrenia. Schizophrenia Research, 2022, 249, 47-55.	2.0	7

#	Article	IF	Citations
109	Bitopertin in schizophrenia: glass half full?. Lancet Psychiatry,the, 2016, 3, 1092-1093.	7.4	6
110	Impaired Fixation-Related Theta Modulation Predicts Reduced Visual Span and Guided Search Deficits in Schizophrenia. Cerebral Cortex, 2020, 30, 2823-2833.	2.9	6
111	What can the study of first impressions tell us about attitudinal ambivalence and paranoia in schizophrenia?. Psychiatry Research, 2016, 238, 86-92.	3.3	5
112	Efficacy of Transcranial Direct Current Stimulation to Improve Insight in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Schizophrenia Bulletin, 2022, 48, 1284-1294.	4.3	5
113	Excitatory Amino Acids in Schizophrenia: Both What You Have, and What You Do With Them. Biological Psychiatry, 2018, 83, 470-472.	1.3	4
114	Relationships between Diffusion Tensor Imaging and Resting State Functional Connectivity in Patients with Schizophrenia and Healthy Controls: A Preliminary Study. Brain Sciences, 2022, 12, 156.	2.3	3
115	The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures. Schizophrenia Research: Cognition, 2020, 19, 100161.	1.3	2
116	Translational Mechanistic Biomarkers for the 21st Century. American Journal of Psychiatry, 2021, 178, 893-895.	7.2	1
117	Madness in the garden or worm in the apple?. Trends in Cognitive Sciences, 2002, 6, 187.	7.8	0
118	Computational mapping of brain networks. , 2016, , .		0